News & Media
- 21 May 2021IPO Watch: Argenica Therapeutics developing drugs for brain recovery
- 13 Jun 2021Argenica Therapeutics (ASX:AGN) lists on ASX
- 11 Jun 2021Argenica Therapeutics prepares for clinical trials of novel stroke treatment
- 10 Jun 2021Perth biotech Argenica Therapeutics set for ASX listing
- 09 Jun 2021Argenica Therapeutics gears up for clinical trial of promising novel stroke treatment
- 03 Jun 2021Perron & UWA to reap $70m Windfall
- 12 Jul 2021Developing therapeutics to reduce brain damage after strokeReference: ShareCafe
- 12 Jul 2021Hidden Gems Webinar Recap – ZLD, WTL, AGN, CLAReference: ShareCafe
- 05 Jul 2021Dr Boreham’s Crucible: Don’t cry for me, ArgenicaReference: Stockhead
- 30 Sep 2021Argenica Therapeutics commences preparations for phase 1 clinical trial of stroke-treatment drug ARG-007Reference: Small Caps
- 30 Sep 2021Argenica Therapeutics commences preparations for Phase 1 clinical trial of stroke-treatment drug ARG-007Reference: Small Caps
- 15 Sep 2021Argenica (ASX:AGN) achieves manufacturing milestonesReference: The Market Herald
- 15 Sep 2021Argenica (ASX:AGN) achieves manufacturing milestonesReference: The Market Herald
- 14 Sep 2021Argenica Therapeutics produces GMP-grade ARG-007 for prevention of brain tissue death in stroke patientsReference: Small Caps
- 14 Sep 2021Argenica Therapeutics produces GMP-grade ARG-007 for prevention of brain tissue death in stroke patientsReference: Small Caps
- 18 Oct 2021Can this biotech tap into a $183 billion market by buying time for stroke patients?Reference: The Sentiment
- 18 Oct 2021Argenica Therapeutics to start phase 1 clinical trials early next yearReference: Small Caps
- 01 Oct 2021New frontier in brain injury treatmentReference: Chamber of Commerce and Industry WA
- 03 Nov 2021Argenica Therapeutics reveals positive pre-clinical results of stroke drug ARG-007 in HIEReference: Smalls Caps
- 31 Dec 2021IPO Watch: ASX IPOs in 2021 were up 14 per cent on average; here are the best performersReference: Stockhead
- 30 Dec 2021Here’s Why We’re Not Too Worried About Argenica Therapeutics’ (ASX:AGN) Cash Burn SituationReference: Simply Wall Street
- 24 Jan 2022Argenica Therapeutics completes pre-clinical toxicology studies of stroke drugReference: Small Caps
- 13 Jan 2022Argenica Therapeutics secures experienced professional to lead clinical development of stroke drugReference: Small Caps
- 24 Feb 2022Argenica Therapeutics moves closer to clinical trials after completing genotoxicity studies on ARG-007Reference: Small Caps
- 21 Mar 2022Argenica Therapeutics publishes scientific paper on ARG-007 ahead of clinical trialsReference: Small Caps
- 27 Apr 2022Argenica Therapeutics toxicology studies indicate key findings ahead of ARG-007 clinical trialReference: Small Caps
- 19 May 2022Argenica Therapeutics moves closer to phase 1 in-human trials of ARG-007 for strokeReference: Small Caps
- 10 May 2022Episode 13: Dr Liz Dallimore, CEO of Argenica TherapeuticsReference: Find the Front
- 05 May 2022Argenica Therapeutics (ASX:AGN) successfully completes safety studiesReference: The Market Herald
- 05 May 2022Argenica steps closer to clinical studies of stroke drug ARG-007 following positive preclinical safety resultsReference: Small Caps
- 03 Jun 2022Argenica Therapeutics tops up bank balance with $5.5m placement to advance ARG-007 in other neurological conditionsReference: Small Caps
- 03 Jul 2022Argenica Therapeutics reports positive findings from peer-reviewed study of stroke drug ARG-007Reference: Small Caps
- 10 Aug 2022New drug shows promising results for stroke sufferersReference: 9 News
- 07 Sep 2022Argenica begins clinical trials of drug that could protect your brain during a strokeReference: The Sentiment
- 07 Sep 2022Argenica Therapeutics gains ethics approval for phase 1 clinical trial of stroke drug ARG-007Reference: Small Caps
- 20 Jan 2023Biotech company secures grant for brain injury researchReference: Business News
- 20 Jan 2023Argenica Therapeutic (ASX:AGN) receives $1.2m grant for traumatic brain injury projectReference: The Market Herald
- 09 Feb 2023Argenica Therapeutics (ASX:AGN) pre-clinical data points to potential new Alzheimer’s treatmentReference: The Market Herald
- 09 Feb 2023ASX Health Stocks: Argenica rockets by 30pc after showing potential breakthrough on Alzheimer’sReference: Stockhead
- 31 Mar 2023Argenica secures significant non-dilutive funding for preclinical studies into newborn brain injuryReference: Stockhead
- 26 Mar 2023Argenica Therapeutics (ASX:AGN) – Broker Briefing Biotech & Nutrition Investor Webinar – March 2023Reference: Broker Briefing
- 15 Mar 2023ASX Small & Mid Cap Conference Argenica Therapeutics LimitedReference: Proactive Investor
- 06 Mar 2023ARG-007 in Phase-1 trial, makes preparations for Phase-2Reference: Stockhead
- 22 Apr 2023Argenica Therapeutics (ASX:AGN) – Webinar PresentationReference: ShareCafe Hidden Gems
- 20 Apr 2023Argenica’s latest HIE trial results show prolonged reduction in brain injuryReference: Stockhead
- 06 Apr 2023Stock Insiders: Argenica progresses to Phase 2 clinical trial in stroke patients with ARG-007Reference: Stockhead
- 22 Jun 2023Argenica’s ARG-007 Shows Promise in Treating Traumatic Brain InjuryReference: Stockhead
- 20 Jun 2023Argenica raises AU$4M to advance neuroprotective agent in ischemic strokeReference: BioWorld
- 12 Jun 2023Perth developed drug helps babies with brain injuries from traumatic birthsReference: Perth Drive
- 19 Jul 2023Argenica Continues to Stride Forward in Phase 2 Clinical Trial of Stroke TherapyReference: Stockhound
- 19 Jul 2023Argenica Submits Ethics Application to Kick Off Phase 2 Stroke Treatment TrialReference: Stockhead
- 22 Aug 2023Redefining the CEO role to encourage more women to take on the mantleReference: Busy Continent
- 04 Aug 2023#9News can show you a new drug that’s tackling concussion head-onReference: 9 News
- 01 Aug 2023What our biotech sector can learn from BostonReference: Medical Forum Magazine
- 22 Sep 2023Perth developed drug, ARG-007, shows encouraging signs to prevent impacts of traumatic brain injuriesReference: The West Australian
- 06 Sep 2023Strokes cost the Australian economy billions, but these biotech players could change thatReference: The Australian
- 06 Sep 202390 Seconds With… Dr Liz Dallimore, Argenica Therapeutics (ASX:AGN)Reference: Stockhead
- 05 Sep 2023The right medical combinationReference: Market Open
- 04 Sep 2023Argenica Therapeutics (ASX:AGN) CEO & Managing Director Dr Liz DallimoreReference: The Watchlist
- 23 Oct 2023$AGN Argenica Therapeutics is developing drugs which focus on preventing brain injuryReference: The Market Bull
- 18 Oct 2023Groundbreaking: This drug could be ‘significantly effective’ at treating brain damage in newbornsReference: Stockhead
- 05 Oct 2023Perth stroke treatment hits phase 2Reference: Medical Forum
- 04 Oct 2023Argenica Therapeutics greenlit to launch Phase II trials into stroke treatmentReference: Clinical Trials Arena
- 06 Nov 2023Stroke Trial – Jenny SeatonReference: Curtin FM
- 03 Nov 2023Data shows Argenica’s drug inhibits another main cause of Alzheimer’s diseaseReference: Stockhead
